Literature DB >> 17488768

Renin: friend or foe?

Morris J Brown1.   

Abstract

Renin maintains blood pressure through vasoconstriction when there is inadequate salt to maintain volume. In populations where blood pressure is more often high than low, and vascular death more common than haemorrhage or dehydration, therapeutic reductions in renin secretion or response are valuable. Whether long-term benefits are due entirely to blood pressure reduction remains unproved. The pathway can be blocked at its rate-limiting step (beta blockade or direct renin inhibition), the synthesis of the active product, angiotensin II, or at the receptor for angiotensin. Because renin and sodium are the two main factors in blood pressure control, and renin levels vary inversely with sodium load, blood pressure control requires a combination of natriuresis and blocking the consequential increase in renin activity. Being a large and stable molecule, renin is among the easiest and cheapest of hormone measurements. Understanding the simple biochemistry and physiology of renin permits optimal use of the drugs acting to raise or suppress this hormone.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17488768      PMCID: PMC1955008          DOI: 10.1136/hrt.2006.107706

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  81 in total

Review 1.  Neural control of the kidney: functionally specific renal sympathetic nerve fibers.

Authors:  G F DiBona
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2000-11       Impact factor: 3.619

2.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

3.  Renin and prorenin: advances and declines in methodology.

Authors:  J E Sealey; J H Laragh
Journal:  Clin Chem       Date:  1996-07       Impact factor: 8.327

Review 4.  Recent advances in the molecular genetics of hypertension.

Authors:  R A Shimkets; R P Lifton
Journal:  Curr Opin Nephrol Hypertens       Date:  1996-03       Impact factor: 2.894

5.  Plasma renin activity and plasma prorenin are not suppressed in hypertensives surviving to old age.

Authors:  P Trenkwalder; G D James; J H Laragh; J E Sealey
Journal:  Am J Hypertens       Date:  1996-07       Impact factor: 2.689

Review 6.  The renin-angiotensin-aldosterone system: a specific target for hypertension management.

Authors:  M R Weir; V J Dzau
Journal:  Am J Hypertens       Date:  1999-12       Impact factor: 2.689

7.  Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT).

Authors:  M J Brown; C R Palmer; A Castaigne; P W de Leeuw; G Mancia; T Rosenthal; L M Ruilope
Journal:  Lancet       Date:  2000-07-29       Impact factor: 79.321

8.  Clinical validation of renin monoclonal antibody-based sandwich assays of renin and prorenin, and use of renin inhibitor to enhance prorenin immunoreactivity.

Authors:  F H Derkx; R J de Bruin; J M van Gool; M J van den Hoek; C C Beerendonk; F Rosmalen; P Haima; M A Schalekamp
Journal:  Clin Chem       Date:  1996-07       Impact factor: 8.327

9.  Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study.

Authors:  C E Mogensen; S Neldam; I Tikkanen; S Oren; R Viskoper; R W Watts; M E Cooper
Journal:  BMJ       Date:  2000-12-09

10.  Effects of captopril related to increased levels of prostacyclin and angiotensin-(1-7) in essential hypertension.

Authors:  M Luque; P Martin; N Martell; C Fernandez; K B Brosnihan; C M Ferrario
Journal:  J Hypertens       Date:  1996-06       Impact factor: 4.844

View more
  24 in total

Review 1.  Therapeutic potential of vaccines in the management of hypertension.

Authors:  Morris J Brown
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 2.  Molecular and clinical investigations in patients with low-renin hypertension.

Authors:  Isla S Mackenzie; Morris J Brown
Journal:  Clin Exp Nephrol       Date:  2008-08-15       Impact factor: 2.801

Review 3.  Now that we have a direct renin inhibitor, what should we do with it?

Authors:  Alice Stanton
Journal:  Curr Hypertens Rep       Date:  2008-06       Impact factor: 5.369

Review 4.  Success and failure of vaccines against renin-angiotensin system components.

Authors:  Morris J Brown
Journal:  Nat Rev Cardiol       Date:  2009-08-25       Impact factor: 32.419

Review 5.  Pharmacological interventions into the renin-angiotensin system with ACE inhibitors and angiotensin II receptor antagonists: effects beyond blood pressure lowering.

Authors:  Rainer Düsing
Journal:  Ther Adv Cardiovasc Dis       Date:  2016-04-27

Review 6.  Is there a blood pressure lowering effect of MRAs in heart failure? An overview and meta-analysis.

Authors:  George Bazoukis; Costas Thomopoulos; Gary Tse; Costas Tsioufis
Journal:  Heart Fail Rev       Date:  2018-07       Impact factor: 4.214

Review 7.  Angiotensin inhibition and longevity: a question of hydration.

Authors:  Simon N Thornton
Journal:  Pflugers Arch       Date:  2010-12-17       Impact factor: 3.657

Review 8.  The Pharmacogenomic and Metabolomic Predictors of ACE Inhibitor and Angiotensin II Receptor Blocker Effectiveness and Safety.

Authors:  Hania K Flaten; Andrew A Monte
Journal:  Cardiovasc Drugs Ther       Date:  2017-08       Impact factor: 3.727

9.  Differential associations between renal function and "modifiable" risk factors in patients with chronic heart failure.

Authors:  Tom D J Smilde; Kevin Damman; Pim van der Harst; Gerjan Navis; B Daan Westenbrink; Adriaan A Voors; Frans Boomsma; Dirk J van Veldhuisen; Hans L Hillege
Journal:  Clin Res Cardiol       Date:  2008-10-31       Impact factor: 5.460

Review 10.  Rationale for triple fixed-dose combination therapy with an angiotensin II receptor blocker, a calcium channel blocker, and a thiazide diuretic.

Authors:  Massimo Volpe; Giuliano Tocci
Journal:  Vasc Health Risk Manag       Date:  2012-06-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.